Generation of Cell Banks and Biomarker Isolation From Patients With Amyotrophic Lateral Sclerosis (ALS) (HCD-SLA)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: sampling blood.
- Who it may be relevant to
- Registry conditions: Amyotrophic Lateral Sclerosis (ALS). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Generation of Skin Fibroblast Banks, Urine-derived Cells and Biomarker Isolation From Patients With Amyotrophic Lateral Sclerosis (Als)
Overview
The aim of this research is to establish different cell banks from patients with amyotrophic lateral sclerosis (ALS).
Detailed description
The objective of this research is to:
* Create banks of skin fibroblasts from skin biopsy samples * Create banks of urine-derived cells (UDCs) from urine samples * Build a collection of blood samples to enable isolation of biomarkers.
Interventions
- Other sampling blood
3 types of sampling : urine, skin and blood.
Primary outcome measures
- Cell banking [Time frame: 8 months]
Eligibility criteria
Inclusion criteria
- Subjects over 18 years old;
- Subjects who have given their consent and signed an informed, free and express consent form;
- Subjects with diagnosed ALS;
- Subjects affiliated to or benefiting from a social security scheme.
Exclusion criteria
- Subjects with contraindications to the collection of biological samples (blood, skin, urine).
- Subjects undergoing treatment likely to affect hemostasis (anticoagulants, platelet anti-aggregants, etc.) in the month prior to inclusion and during the study;
- Subjects with hereditary or acquired haemostasis disorders;
- Subjects who have undergone physical treatment (radiotherapy, etc.) on the area to be biopsied in the last 6 months;
- Lidocaine-intolerant subjects;
- Subjects who have reached the age of majority and are subject to a protective measure or are unable to express their consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07099066 · 2025-A00776-43